GEN Exclusives

More »

GEN News Highlights

More »
Mar 7, 2007

Aeras Commits $5M to Crucell for Continued TB Research

  • Crucell will receive up to $5 million from Aeras Global TB Vaccine Foundation to support the advanced development of the candidate AdVac-based tuberculosis vaccine.

    "This technology, which is based on one of the most advanced vector delivery systems for induction of cellular immunity, represents an important part of the portfolio of vaccines we are developing against tuberculosis," states Jerald C. Sadoff, president & CEO of Aeras Global TB Vaccine Foundation.

    In March 2004, Aeras and Crucell entered into a collaborative agreement for the development of a PER.C6® and AdVac®-based TB vaccine. The vaccine entered a Phase I trial in October 2006.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »